EP1604988A1 — Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
Assigned to Sanofi Aventis Deutschland GmbH · Expires 2005-12-14 · 20y expired
What this patent protects
The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R<sup>1</sup> and R<sup>2</sup> given below in the text, as well as their physiologically acceptable salts, methods for producing t…
USPTO Abstract
The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R<sup>1</sup> and R<sup>2</sup> given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals.These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3β (glycogen synthase kinase-3β).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.